Biogen to acquire RayThera biotechnology company for up to one billion dollars
Business · 4 July 2026
Written by AI from multiple news reports
Biogen has agreed to buy the small biotechnology firm RayThera for up to one billion dollars, with the deal expected to close in the third quarter of 2026.
RayThera was founded in 2023 and works on treatments for diseases of the immune system. The company currently has three drug candidates, though none have entered human trials yet. Its most advanced candidate is due to begin Phase 1 testing in early Q3 2026. Biogen will take over development and manufacturing of all three.
The purchase price includes an upfront sum plus additional payments linked to clinical and regulatory progress. RayThera has shared very little public information about its drugs, describing them only as anti-inflammatory.